Last $2.80 USD
Change Today -0.15 / -5.08%
Volume 4.6K
As of 11:50 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

tapimmune inc (TPIV) Snapshot

Open
$2.70
Previous Close
$2.95
Day High
$2.95
Day Low
$2.70
52 Week High
05/6/13 - $9.00
52 Week Low
10/8/13 - $0.62
Market Cap
4.1M
Average Volume 10 Days
10.0K
EPS TTM
--
Shares Outstanding
1.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TAPIMMUNE INC (TPIV)

Related News

No related news articles were found.

tapimmune inc (TPIV) Related Businessweek News

No Related Businessweek News Found

tapimmune inc (TPIV) Details

TapImmune Inc., a development stage company, engages in the discovery and development of immunotherapeutics for the treatment of cancer, as well as therapies for infectious diseases, autoimmune disorders, and transplant tissue rejection. The company is also involved in the development of HER2/neu, a vaccine technology, which is in Phase I human clinical trials for the treatment of breast cancer. Its products also include TAP cancer vaccine, which is under preclinical toxicology and clinical manufacturing studies for the treatment of breast cancer, prostate cancer, lung cancer, liver cancer, melanoma, renal cancer, and colorectal cancer. The company has a technology option agreement with Mayo Foundation for the evaluation of HER2/neu, as well as has a research license and option agreement with Crucell Holland B.V. TapImmune Inc. was founded in 1999 and is based in Seattle, Washington.

tapimmune inc (TPIV) Top Compensated Officers

Executive Chairman, Chief Executive Officer, ...
Total Annual Compensation: $180.0K
Vice President of Development, Member of Advi...
Total Annual Compensation: $60.0K
Compensation as of Fiscal Year 2013.

tapimmune inc (TPIV) Key Developments

TapImmune, Inc. announced delayed annual 10-K filing

On 04/01/2014, TapImmune, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

TapImmune, Inc. will Change its Ticker to TPIV from TPIV.D

Effective March 25, 2014, TapImmune, Inc. will change its Pink Sheets LLC stock ticker symbol to TPIV from TPIV.D.

TapImmune Inc. Signs Exclusive Option Agreement for New Phase 1 Clinical Program in Breast and Ovarian Cancer

TapImmune Inc. signed an exclusive option agreement for a set of unique peptide epitopes targeting Folate Receptor Alpha in both breast cancer and ovarian cancer. Folate receptor alpha is expressed in nearly 50% of breast cancers and in addition, over 95% of ovarian cancers, for which the only treatment options are surgery and chemotherapy, leaving a very important and urgent clinical need for a new therapeutic. Time to recurrence is relatively short for this type of cancer and survival prognosis is extremely poor after recurrence. In the US alone, there are approximately 30,000 ovarian cancer patients newly diagnosed every year. A 22 patient Phase 1 clinical trial is underway. The trial is fully enrolled, closed and Phase 2 advancement will be assessed in late 2014. No serious adverse events have occurred to date and more information and immune response data will be made available over the course the trial. This is second late stage Phase 1 clinical trial in the TapImmune portfolio along with the Her2/neu breast cancer sponsored trial underway at Mayo Clinic in Rochester MN.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TPIV:US $2.80 USD -0.15

TPIV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TPIV.
View Industry Companies
 

Industry Analysis

TPIV

Industry Average

Valuation TPIV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAPIMMUNE INC, please visit www.tapimmune.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.